The History of Experimental Heterotopic and Orthotopic Heart Transplantation Before Cardiopulmonary Bypass

2012 ◽  
pp. 79-83
Author(s):  
Tyson A. Fricke ◽  
Igor E. Konstantinov
Keyword(s):  
Cardiopulmonary Bypass ◽  
Heart Transplantation ◽  
Orthotopic Heart Transplantation ◽  
History Of

scholarly journals Sudden cardiac arrest after late permanent pacemaker implantation in a heart transplant patient

2021 ◽  
Vol 0 (Ahead of Print) ◽  
Author(s):  
Yavuzer Koza ◽  
Oguzhan Birdal ◽  
Sidar Siyar Aydın ◽  
Ferih Ozcanlı ◽  
Hakan Tas
Keyword(s):  
Heart Transplantation ◽  
Transplant Patient ◽  
Cardiopulmonary Arrest ◽  
Sudden Cardiac Arrest ◽  
Pacemaker Implantation ◽  
Early Period ◽  
Permanent Pacemaker ◽  
Orthotopic Heart Transplantation ◽  
History Of ◽  
Pulse Steroid

Bradycardia during the early period following heart transplantation frequently occurs with an incidence of 14 to 44% and it is usually self-limited. The incidence of late bradycardia (from 30 days to more than 5 or 6 months after transplantation) has been reported to be 1.5%. A 33-year-old male patient with a history of orthotopic heart transplantation in 2013 presented with complaints of dizziness and near syncope. A DDDR permanent pacemaker was implanted for sinus pauses exceeding 3 seconds recorded on Holter examination. Shortly after the procedure, he developed sudden cardiovascular collapse. Cardiopulmonary resuscitation was performed and a pulse steroid treatment (2 grams of methylprednisolone) was given. After 2 days, the patient was extubated. While making preparations for re-transplantation, cardiopulmonary arrest developed again and he died. Sinus pause may be a clue for rejection and is an important finding in predicting clinical course.

P1883Arrhythmias in transplanted hearts: Lessons from Europes largest cohort of patients who underwent orthotopic heart transplantation

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
L Bergau ◽  
M El-Hamriti ◽  
S Molatta ◽  
K Alzain ◽  
V Rubesch-Kuetemeyer ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Heart Transplantation ◽  
Large Cohort ◽  
Background Information ◽  
Orthotopic Heart Transplantation ◽  
Atrial Ablation ◽  
Successful Transplantation ◽  
History Of ◽  
Atrial Fibrillation And Flutter ◽  
Supraventricular Tachycardias

Abstract Introduction Cardiac arrhythmias are regulary seen in patients following orthotopic heart transplantation (OHT). So far, there is no data available about the prevalence in a large cohort. Methods We retrospectively screened our database for subjects with OHT who received inpatient or outpatient treatment in our center between January 2000 and December 2018. All these patients were carefully reviewed with special attention to rhythm disturbances after successful transplantation. Results We identified a total number of 1890 subjects with history of OHT being treated in our center during the pre-defined time-period. The prevalence of supraventricular tachycardias was as follows: atrial fibrillation/atypical flutter and atrial ectopy 10%, AV-node-re-entry tachycardia 3%, typical atrial flutter 2% and higher degree AV-Block or Sick-Sinus-Syndrom (SSS) was 6%. Sustained ventricular tachycardia or ventricular premature contractions were present in 2%. Regarding the patients with arrhythmias, 13% received catheter ablation for arrhythmias, thereof 53% an atrial ablation (24% left atrial ablation), the remainder received a ventricular ablation. Conclusion In this very large cohort and following a long observational time, there was a higher incidence of atrial arrhythmias in patients following OHT as reported in healthy subjects with an emphasis on atrial fibrillation and flutter. This data gives a valuable background information on morbidity following OHT.

scholarly journals The effect of a donor's history of active substance on outcomes following orthotopic heart transplantation☆

2007 ◽  
Vol 31 (3) ◽  
pp. 452-456 ◽  
Author(s):  
Kenneth J. Shea ◽  
Nikolai A Sopko ◽  
Kristin Ludrosky ◽  
Katherine Hoercher ◽  
Nicholas G. Smedira ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Active Substance ◽  
Orthotopic Heart Transplantation ◽  
History Of

scholarly journals Switch from minimally invasive biventricular mechanical support to cardiopulmonary bypass during heart transplant

2020 ◽  
Vol 59 (1) ◽  
pp. 271-273
Author(s):  
Fabrizio Settepani ◽  
Stefano Maria Marianeschi ◽  
Alessandro Costetti ◽  
Claudio Francesco Russo
Keyword(s):  
Cardiopulmonary Bypass ◽  
Surgical Technique ◽  
Minimally Invasive ◽  
Heart Transplantation ◽  
Inferior Vena ◽  
Vena Cava ◽  
Venous Drainage ◽  
Ascending Aorta ◽  
Orthotopic Heart Transplantation ◽  
Mechanical Support

Abstract An easily reproducible surgical technique to switch from percutaneous minimally invasive biventricular mechanical support to cardiopulmonary bypass during heart transplantation is illustrated. After cannulation of the distal ascending aorta with a standard arterial cannula, the ProtekDuo® cannula and the ProtekSolo® Transseptal cannula were partially retracted to reach the superior and inferior vena cava, respectively, and connected to the pump circuit for the venous drainage. With this cardiopulmonary bypass configuration, orthotopic heart transplantation was routinely performed and, at the end of the procedure, the 2 cannulas were uneventfully removed.

scholarly journals Anticoagulation with Argatroban in a Patient with Heparin-Induced Thrombocytopenia and Renal Insufficiency Undergoing Orthotopic Heart Transplantation

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Michael Stuart Green ◽  
Johann Mathew ◽  
Christopher Ryan Hoffman ◽  
Henry Liu
Keyword(s):  
Heart Failure ◽  
Cardiac Surgery ◽  
Cardiopulmonary Bypass ◽  
Heart Transplantation ◽  
Decompensated Heart Failure ◽  
Orthotopic Heart Transplantation ◽  
Clinical Use ◽  
Heparin Induced Thrombocytopenia ◽  
Advantages And Disadvantages ◽  
Immune Mediated

Unfractionated heparin is the anticoagulant of choice for cardiac surgery that requires cardiopulmonary bypass. However, it can cause serious side effects like heparin-induced thrombocytopenia (HIT), an immune-mediated process where antibodies are directed against heparin and platelet 4 complexes. In such cases, alternative pharmacologic strategies are implemented to facilitate safe bypass conditions. A woman with severe decompensated heart failure was heparinized for intra-aortic balloon pump and subsequent LVAD placement. On day 6, a fall in platelets from 113,000 to 26,000 was noted. She was diagnosed with HIT. Heparin was discontinued and replaced with an argatroban infusion for the duration of her care until heart transplantation was completed. We review the mechanism, diagnosis, and complications of HIT. We discuss cardiopulmonary bypass and its relation to heparin, HIT, and heparin alternatives. We discuss argatroban’s relevant pharmacology, clinical use, advantages, and disadvantages.

Heterotopic Heart Transplantation: The United States Experience

2014 ◽  
Vol 17 (3) ◽  
pp. 132 ◽  
Author(s):  
Jama Jahanyar ◽  
Michael M. Koerner ◽  
Ali Ghodsizad ◽  
Matthias Loebe ◽  
George P. Noon
Keyword(s):  
United States ◽  
Heart Transplantation ◽  
The United States ◽  
Orthotopic Heart Transplantation ◽  
Size Mismatch ◽  
Heterotopic Heart Transplantation ◽  
Feasible Option ◽  
History Of ◽  
States Experience ◽  
Or History

<p><b>Introduction:</b> More than 3 decades have passed since the first heterotopic heart transplantation (HHT) was reported. Nowadays, this surgical technique is used rarely, and only in patients who do not qualify for standard orthotopic heart transplantation (OHT). Current indications mainly comprise refractory pulmonary hypertension and a donor-recipient size mismatch (>20%). The objective of this study was to analyze the United States experience with HHT.</p><p><b>Patients and Methods:</b> The United Network for Organ Sharing (UNOS) database between 1987 and 2007 was analyzed. Patients who underwent heart transplantation were enrolled in this study. Patients with missing transplant dates or history of retransplantation were excluded.</p><p><b>Results:</b> A total of 41,379 patients underwent OHT and 178 HHT; 32,361 and 111 patients, respectively, were enrolled. Overall 1-, 5-, and 10-year survival was significantly (<i>P</i> < .001) better in OHT (87.7%, 74.4%, 54.4%) than HHT patients (83.8%, 59%, 35.1%). Survival in patients with transpulmonary gradients (TPG) >15 mmHg was 86.6 %, 73.3%, and 57.4% in the OHT and 93.8%, 64.8%, and 48.6% in the HHT group (<i>P</i> = .35). Pretransplant criteria (HHT versus OHT) with statistically significant differences (<i>P</i> < .05) were as follows (mean + SD): recipient weight, 78.9 + 19.9 versus 74.1 + 23.4 kg; recipient height, 174.9 + 13.9 versus 168 + 25.1 cm; and TPG 12.1 + 7.2 versus 9.6 + 6.3 mmHg.</p><p><b>Conclusions:</b> The results show that HHT remains a feasible option in a highly selected patient population, with overall good results.</p>

scholarly journals Heart Transplantation in Mustard Patients Bridged With Continuous Flow Systemic Ventricular Assist Device - A Case Report and Review of Literature

2021 ◽  
Vol 8 ◽  
Author(s):  
Rody G. Bou Chaaya ◽  
Joel W. Simon ◽  
Mark Turrentine ◽  
Jeremy L. Herrmann ◽  
William Aaron Kay ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Transplantation ◽  
Ventricular Assist Device ◽  
Continuous Flow ◽  
Orthotopic Heart Transplantation ◽  
Review Of Literature ◽  
Assist Device ◽  
Ventricular Assist ◽  
Mustard Operation ◽  
History Of

Thirty four-year-old male with history of D-transposition of the great arteries (D-TGA) who underwent Mustard operation at 14 months of age presented in cardiogenic shock secondary to severe systemic right ventricular failure. Catheterization revealed significantly increased pulmonary pressures. Due to the patient's inotrope dependence and prohibitive pulmonary hypertension, he underwent implantation of a Heart Ware HVAD® for systemic RV support. Within 4 months of continuous flow ventricular assist device (VAD) implantation complete normalization of pulmonary vascular resistance (PVR) was achieved. He ultimately underwent orthotopic heart transplantation with favorable outcomes. This is the second report of complete normalization of PVR following VAD implantation into a systemic RV in &lt;4 months. We conducted a thorough literature review to identify Mustard patients that received systemic RV VAD as a bridge to a successful heart transplantation. In this article, we summarize the outcomes and focus on pulmonary hypertension reversibility following VAD implant.

A History of Orthotopic Heart Transplantation

2005 ◽  
Vol 13 (4) ◽  
pp. 190-196 ◽  
Author(s):  
Trip J. Meine ◽  
Stuart D. Russell
Keyword(s):  
Heart Transplantation ◽  
Orthotopic Heart Transplantation ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document